Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHN WILEY & SONS, INC.

(JW.A)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

John Wiley & Sons : Which Medications Are Most Toxic to the Liver?

05/05/2021 | 01:09am EDT

A new study published in the British Journal of Clinical Pharmacology ­provides insights on how common hospitalized patients develop liver injury from taking different medications.

When investigators analyzed the records of 156,570 hospitalized patients, they found 499 cases of drug-induced liver injury (DILI), for an incidence of 0.32%. Anti-infective agents, cancer medications, and nonsteroidal anti-inflammatory drugs were the major categories of drugs causing DILI, and the highest incidence was due to voriconazole (an antifungal medication). Patients with high cholesterol, cardiovascular disease, pre-existing liver disease, and prior surgeries faced a higher risk of DILI.

'We have carried out DILI-related real-world study with the help of information technology to provide a more accurate reference for safe and rational drug use,' said corresponding author DaiHong Guo, of the Chinese People's Liberation Army General Hospital, in Beijing.

Additional Information

Link to Study: https://onlinelibrary.wiley.com/doi/10.1111/bcp.14847

About Journal

Published on behalf of the British Pharmacological Society, the British Journal of Clinical Pharmacology features papers and reports on all aspects of drug action in humans: review articles, mini review articles, original papers, commentaries, editorials and letters. The Journal enjoys a wide readership, bridging the gap between the medical profession, clinical research and the pharmaceutical industry. It also publishes research on new methods, new drugs and new approaches to treatment. The Journal is recognised as one of the leading publications in its field. It is online only, publishes open access research through its OnlineOpen programme and is published monthly.

About Wiley

Wiley drives the world forward with research and education. Through publishing, platforms and services, we help students, researchers, universities, and corporations to achieve their goals in an ever-changing world. For more than 200 years, we have delivered consistent performance to all of our stakeholders. The Company's website can be accessed at www.wiley.com.

Disclaimer

John Wiley & Sons Inc. published this content on 05 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 May 2021 05:08:02 UTC.


ę Publicnow 2021
All news about JOHN WILEY & SONS, INC.
05/05JOHN WILEY & SONSá : New Study Identifies Quality Measures for End-of-Life Care ..
PU
05/05JOHN WILEY & SONSá : Many Patients With Cancer Are Experiencing Loneliness and R..
PU
05/05JOHN WILEY & SONSá : Which Medications Are Most Toxic to the Liver?
PU
05/05JOHN WILEY & SONSá : Do Bacteria in the Mouth Affect Risk of Developing Rheumato..
PU
05/05JOHN WILEY & SONSá : Erythropoietin Treatments May Increase Hip Fracture Risk in..
PU
05/05JOHN WILEY & SONSá : How Accurate Are Virtual Assessments of Cognitive Function?
PU
05/05JOHN WILEY & SONSá : The Online Learning Needs of Students Across Different Grad..
PU
05/05JOHN WILEY & SONSá : English as a Medium of Instruction in Higher Education Acro..
PU
05/05JOHN WILEY & SONSá : Light Pollution at Night Affects the Calls of Migratory Bir..
PU
05/05JOHN WILEY & SONSá : New Tool Offers Personalized, Low Environmental Impact, Hea..
PU
More news
Financials (USD)
Sales 2021 1 904 M - -
Net income 2021 139 M - -
Net Debt 2021 938 M - -
P/E ratio 2021 24,9x
Yield 2021 2,22%
Capitalization 3 435 M 3 435 M -
EV / Sales 2021 2,30x
EV / Sales 2022 2,19x
Nbr of Employees 6 900
Free-Float 52,3%
Chart JOHN WILEY & SONS, INC.
Duration : Period :
John Wiley & Sons, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHN WILEY & SONS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 55,33 $
Last Close Price 61,72 $
Spread / Highest target 0,45%
Spread / Average Target -10,3%
Spread / Lowest Target -22,2%
EPS Revisions
Managers and Directors
NameTitle
Brian A. Napack President, Chief Executive Officer & Director
John Anthony Kritzmacher Chief Financial Officer & Executive VP-Operations
Jesse C. Wiley Non-Executive Chairman
Aref Matin Chief Technology Officer & Executive VP
Raymond W. McDaniel Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHN WILEY & SONS, INC.34.17%3 414
S&P GLOBAL INC.15.51%91 465
RELX PLC1.79%49 331
THOMSON REUTERS CORPORATION9.91%46 733
MSCI INC.3.26%38 004
EQUIFAX INC.20.94%28 846